Market Research Logo

Global Hospital Infection Therapeutics Market 2015-2019

About hospital-acquired infections

Hospital-acquired diseases are also known as nosocomial infections that are acquired in hospitals and other healthcare facilities. These infections are classified only when a patient is admitted for reasons other than the infections and are caused by bacteria, fungi, parasites, or viruses. Most common types of hospital-acquired infections are SSIs, UTIs, bloodstream infections, pneumococcal infections, MRSA, and gastrointestinal illnesses. These infections appear between 48 hours and four days after a patient is admitted and are usually related to a treatment of procedure used to treat or diagnose the patient's initial illness or injury. Hospital-acquired diseases are preventable through adherence to strict guidelines and less usage of invasive equipment that must be followed by healthcare professionals while caring for the patient. Anti-infective drugs are used for the treatment of these infections. These infections can be minimized by following proper infection control measures in the hospitals and healthcare institutions.

Technavio's analysts forecast the global hospital infection therapeutics market to grow at a CAGR of 3.24% over the period 2014-2019.

Covered in this report

The report covers the present scenario and growth prospects of the global hospital infection therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of drugs used in the treatment of various hospital-acquired infections such as bloodstream infections, Clostridium difficile infections, hospital-acquired pneumonia, surgical site infections, and urinary tract infections.

Technavio's report, Global Hospital Infection Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global hospital infection therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA
Key vendors
  • Allergan
  • Bayer
  • GlaxoSmithKline
  • Merck
  • Pfizer
Other prominent vendors
  • Abbott Laboratories
  • Achaogen
  • AmpliPhi Biosciences
  • Angelini Pharma
  • Aridis Pharmaceuticals
  • AstraZeneca
  • Durata Therapeutics
  • F. Hoffmann-La Roche
  • Isis Pharmaceuticals
  • Johnson & Johnson
  • Ligand Pharmaceuticals
  • Massachusetts Biological Laboratories
  • Medarex
  • Meiji Seika Pharma
  • Melinta Therapeutics
  • Nektar
  • Novartis
  • Prokarium
  • Sanofi
  • Tetraphase Pharmaceuticals
  • The Medicines Company
  • Valneva
Key market driver
  • Development of multidrug resistant variants
  • For a full, detailed list, view our report
Key market challenge
  • Rise in number of infection control programs
  • For a full, detailed list, view our report
Key market trend
  • Patient assistance programs
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Hospital Infection Therapeutics Market 2015-2019

Technavio recognizes the following companies as the key players in the Global Hospital Infection Therapeutics Market: Allergan, Bayer, GlaxoSmithKline, Merck and Pfizer

Other Prominent Vendors in the market are: Abbott Laboratories, Achaogen, AmpliPhi Biosciences, Angelini Pharma, Aridis Pharmaceuticals, AstraZeneca, Durata Therapeutics, F. Hoffmann-La Roche, Isis Pharmaceuticals, Johnson & Johnson, Ligand Pharmaceuticals, Massachusetts Biological Laboratories, Medarex, Meiji Seika Pharma, Melinta Therapeutics, Nektar, Novartis, Prokarium, Sanofi, Tetraphase Pharmaceuticals, the Medicines Company, and Valneva.

Commenting on the report, an analyst from Technavio’s team said: “Patient assistance programs are expected to boost the growth of the market during the forecast period. Vendors provide co-pay assistance to individuals who purchase the indicated drugs for treating infections. Pfizer's drug Zyvox has a co-pay assistance program to provide financial assistance.”

According to the report, surgeries for cardiac, renal, and gastrointestinal disorders and cesarean section for childbirth are commonly performed currently. Many individuals also choose esthetic enhancement surgeries such as maxillofacial and prosthetic surgeries. This leads to increased exposure to microbes in the hospital environment, thus leading to infections and other complications. Surgeries increase the length of stay in the hospital and individuals are at greater risk of contracting infections.

Further, the report states that generic drugs are similar in quality, dosage form, strength, and efficacy to branded drugs, but are available at lower prices. A branded drug can be manufactured as generic after losing its patent. Many of the anti-infective drugs such as ceftriaxone, ampicillin, ampicillin and sulbactam, and ertapenem, are available as generics in the market.

Companies Mentioned

Allergan, Bayer, GlaxoSmithKline, Merck, Pfizer, Abbott Laboratories, Achaogen, AmpliPhi Biosciences, Angelini Pharma, Aridis Pharmaceuticals, AstraZeneca, Durata Therapeutics, F. Hoffmann-La Roche, Isis Pharmaceuticals, Johnson & Johnson, Ligand Pharmaceuticals, Massachusetts Biological Laboratories, Medarex, Meiji Seika Pharma, Melinta Therapeutics, Nektar, Novartis, Prokarium, Sanofi, Tetraphase Pharmaceuticals, the Medicines Company, Valneva.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
  • Disease overview
    • Understanding disease
    • Modes of transmission
      • Table Types of contact transmission
    • Types of infections
    • Prevention
    • Treatment
    • Epidemiology
    • Economic burden
  • Pipeline analysis
    • Table Global hospital infection treatment market: Pipeline portfolio
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global hospital infection therapeutics market 2014-2019 ($ billions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by drug class
    • Table Global hospital infection therapeutics market segment by drug class
    • Antibacterials
      • Table Types of antibacterial drug by chemical class
    • Antiviral drugs
    • Antifungal drugs
      • Table Types of antifungal drugs by chemical class
  • Market segmentation by type of infections
    • Table Global hospital infection therapeutics market segment by type of infections
    • Urinary tract infections
    • Respiratory tract infections
    • Bloodstream infections
    • Surgical site infections
    • Gastrointestinal infections
      • Table Estimates of hospital-acquired infections occurring in acute care hospitals in the US 2011
      • Table Percentage share of market segment by type of infection 2014
  • Geographical segmentation
    • Segmentation of global hospital infection therapeutics market by geography
      • Table Global hospital infection therapeutics market segment by geography 2014
  • Market drivers
    • Development of multidrug resistant variants
    • Rise in public health awareness
    • Special regulatory designation for pipeline molecules
    • Increase in number of surgical procedures
  • Impact of drivers
    • Table Impact of drivers
    • Rise in number of infection control programs
    • Increased use of generics
    • Lack of proper healthcare infrastructure
  • Market challenges
    • Table Impact of drivers and challenges
  • Market trends
  • Vendor landscape
    • Competitive scenario
    • Market share analysis 2014
      • Table Allergan: Key takeaways
      • Table Allergan: Year-over-year (YoY) growth and revenue generated from net sales of pharmaceutical products 2011-2014 ($ millions)
      • Table Allergan: YoY growth and revenue generated from net product sales of anti-infective 2011-2013 ($ millions)
      • Table Bayer: Key takeaways
      • Table GlaxoSmithKline: Key takeaways
      • Table GlaxoSmithKline: YoY growth and revenue generated from sales of Augmentin 2011-2014 ($ millions)
      • Table GlaxoSmithKline: Revenue generated from sales of Augmentin by region 2011-2014 ($ millions)
      • Table GlaxoSmithKline: YoY growth and revenue generated from sales of other antibacterial drugs 2013-2014 ($ millions)
      • Table Merck: Key takeaways
      • Table Merck: YoY growth and revenue generated from sales of Primaxin 2012-2014 ($ millions)
      • Table Merck: YoY growth and revenue generated from sales of Cancidas 2012-2014 ($ millions)
      • Table Merck: YoY growth and revenue generated from sales of Invanz 2012-2014 ($ millions)
      • Table Merck: YoY growth and revenue generated from sales of Noxafil 2012-2014 ($ millions)
      • Table Pfizer: Key takeaways
      • Table Pfizer: YoY growth and revenue generated from sales of Zyvox 2012-2014 ($ millions)
      • Table Pfizer: YoY growth and revenue generated from sales of Vfend 2012-2014 ($ millions)
      • Table Pfizer: YoY growth and revenue generated from sales of Zithromax and Zmax 2012-2014 ($ millions)
      • Table Pfizer: YoY growth and revenue generated from sales of Diflucan 2012-2014 ($ millions)
      • Table Pfizer: YoY growth and revenue generated from sales of Dalacin and Cleocin 2012-2014 ($ millions)
    • Other prominent vendors
  • Key vendor analysis
    • Allergan
      • Table Allergan: Business segmentation 2014 by revenue
      • Table Allergan: Business segmentation by revenue 2013 and 2014 ($ billions)
      • Table Allergan: Geographical segmentation by revenue 2014
    • Bayer HealthCare
    • GSK
    • Merck & Co
      • Table Geographical segmentation by revenue 2014
      • Table Business segmentation by total revenue 2013 and 2014 ($ billions)
    • Pfizer
      • Table Pfizer in pharmaceutical sector
      • Table Geographical segmentation by revenue 2014
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report